Last $2.34 USD
Change Today +0.24 / 11.43%
Volume 3.6M
GALE On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 08/26/14 All times are local (Market data is delayed by at least 15 minutes).

galena biopharma inc (GALE) Snapshot

Open
$2.11
Previous Close
$2.10
Day High
$2.34
Day Low
$2.10
52 Week High
01/14/14 - $7.77
52 Week Low
04/15/14 - $1.66
Market Cap
276.6M
Average Volume 10 Days
2.5M
EPS TTM
$-0.78
Shares Outstanding
118.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GALENA BIOPHARMA INC (GALE)

Related News

No related news articles were found.

galena biopharma inc (GALE) Related Businessweek News

No Related Businessweek News Found

galena biopharma inc (GALE) Details

Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology treatments that address major unmet medical needs to advance cancer care. Its commercial product includes Abstral, a sublingual tablet, which is used as treatment option for breakthrough cancer pain in patients. The company’s lead product candidate comprise NeuVax (nelipepimut-S or E75), which has completed Phase III clinical trials for preventing the recurrence of breast cancer; and Phase IIb clinical trials in combination with Herceptin for the treatment of breast cancer. It also develops GALE-301 or Folate Binding Protein (FBP), a therapeutic target that has completed Phase II clinical trials for the treatment of ovarian and endometrial cancers; and GALE-401 (Anagrelide CR), which has completed Phase I studies for the treatment of essential thrombocythemia. Galena Biopharma, Inc. has strategic partnership with Dr. Reddy's Laboratories Ltd. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Galena Biopharma, Inc. in September 2011. Galena Biopharma, Inc. was founded in 2003 and is based in Lake Portland, Oregon.

60 Employees
Last Reported Date: 03/17/14
Founded in 2003

galena biopharma inc (GALE) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: $490.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $236.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $127.3K
Compensation as of Fiscal Year 2013.

galena biopharma inc (GALE) Key Developments

Galena Biopharma, Inc. Announces Management Changes

Galena Biopharma, Inc. announced that Mark W. Schwartz, Ph.D., has been appointed as president and chief executive officer, effective immediately. Dr. Schwartz was previously Galena's executive vice president and chief operating officer. He replaces Mark J. Ahn, Ph.D. who has resigned as the president and CEO and as a director of the company to pursue other long held personal and professional goals. It is expected that Dr. Schwartz will also be appointed to Galena's board of directors. Dr. Schwartz brings more than 30 years of experience in the biotechnology and life science industry and was appointed executive vice president and chief operating officer in 2011 following Galena's acquisition of Apthera, Inc. where he served as the company's president and chief executive officer. Prior to Apthera, Dr. Schwartz served for five years as president and CEO of Bayhill Therapeutics.

Galena Biopharma, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Cash Flow Guidance for the Third Quarter 2014

Galena Biopharma, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company announced net revenue was $2,331,000 compared to $0 a year ago. Operating loss was $15,783,000 compared to $7,986,000 for the same period a year ago. Loss before income taxes was $19,941,000 compared to $8,056,000 for the same period a year ago. Net loss was $19,941,000 compared to $9,597,000 for the same period a year ago. Net loss was $9,597,000 compared to $196,000 for the same period a year ago. Basic and diluted net loss per share was $0.17 compared to $0.11 for the same period a year ago. From a cash flow perspective, the company spent $13 million in operating activities compared to $8 million last quarter. For the six months, the company announced net revenue was $4,504,000 compared to $0 a year ago. Operating loss was $27,632,000 compared to $14,597,000 for the same period a year ago. Loss before income taxes was $22,477,000 compared to $20,111,000 for the same period a year ago. Net loss from continuing operations was $18,890,000 compared to $23,313,000 for the same period a year ago. Net loss was $22,477,000 compared to $18,890,000 for the same period a year ago. Basic and diluted net loss per share was $0.19 compared to $0.23 for the same period a year ago. The company, moving forward, expect net operating cash burn to stabilize in the range of $8 million to $10 million per quarter, due to factors including NeuVax Phase III completing enrollment, increasing profitability from commercial operations and expectation that a majority of ongoing legal fees will be reimbursed from insurance carrier.

Galena Biopharma, Inc. to Report Q2, 2014 Results on Aug 11, 2014

Galena Biopharma, Inc. announced that they will report Q2, 2014 results at 5:00 PM, Eastern Standard Time on Aug 11, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GALE:US $2.34 USD +0.24

GALE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Benitec Biopharma Ltd A$1.07 AUD -0.01
Prosensa Holding NV $9.39 USD +0.15
Regulus Therapeutics Inc $7.19 USD +0.26
Silence Therapeutics PLC 215.00 GBp -5.00
Tekmira Pharmaceuticals Corp C$20.93 CAD +1.13
View Industry Companies
 

Industry Analysis

GALE

Industry Average

Valuation GALE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 35.5x
Price/Book 8.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 28.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GALENA BIOPHARMA INC, please visit www.galenabiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.